Healthcare provider profile · identity verified

David Daniel Scheid, MD

Allopathic & Osteopathic Physicians|Internal Medicine · WAXAHACHIE, TX · NPI 1811996168

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David Daniel Scheid, MD received $39.76 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 55.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$39.76

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$21.91	55.1%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$17.85	44.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$39.76	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$21.91	1	2025
Source payment records 2025-10-14 · Novo Nordisk Inc · $21.91 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$17.85	1	2025
Source payment records 2025-10-15 · Lilly USA, LLC · $17.85 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$17.85	1	2025
Source payment records 2025-10-15 · Lilly USA, LLC · $17.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	134	exact normalized	Medicare Part D
Ozempic ozempic	2025	Ozempic	2024	128	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	153	41
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	134	22
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	38	12
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	128	26

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	867	246
Levothyroxine Sodium	Levothyroxine Sodium	554	150
Amlodipine Besylate	Amlodipine Besylate	469	129
Lisinopril	Lisinopril	441	128
Montelukast Sodium	Montelukast Sodium	429	125
Losartan Potassium	Losartan Potassium	405	125
Omeprazole	Omeprazole	381	101
Pantoprazole Sodium	Pantoprazole Sodium	368	131
Ezetimibe	Ezetimibe	324	88
Metoprolol Succinate	Metoprolol Succinate	308	87
Pravastatin Sodium	Pravastatin Sodium	294	82
Metformin Hcl Er	Metformin Hcl	268	75
Rosuvastatin Calcium	Rosuvastatin Calcium	263	79
Furosemide	Furosemide	257	82
Eliquis	Apixaban	246	60
Simvastatin	Simvastatin	227	60
Carvedilol	Carvedilol	224	68
Gabapentin	Gabapentin	214	69
Hydrochlorothiazide	Hydrochlorothiazide	207	67
Tamsulosin Hcl	Tamsulosin Hcl	179	56
Trazodone Hcl	Trazodone Hcl	176	50
Famotidine	Famotidine	174	58
Fluticasone Propionate	Fluticasone Propionate	162	67
Jardiance	Empagliflozin	153	41
Prednisone	Prednisone	153	102
Metoprolol Tartrate	Metoprolol Tartrate	148	42
Alendronate Sodium	Alendronate Sodium	147	40
Meloxicam	Meloxicam	146	53
Alfuzosin Hcl Er	Alfuzosin Hcl	142	46
Duloxetine Hcl	Duloxetine Hcl	142	38
Mounjaro	Tirzepatide	134	22
Celecoxib	Celecoxib	130	38
Tramadol Hcl	Tramadol Hcl	129	38
Ozempic	Semaglutide	128	26
Valsartan	Valsartan	126	36
Potassium Chloride	Potassium Chloride	124	44
Clopidogrel	Clopidogrel Bisulfate	123	38
Pioglitazone Hcl	Pioglitazone Hcl	117	34
Albuterol Sulfate Hfa	Albuterol Sulfate	113	54
Allopurinol	Allopurinol	108	31
Alprazolam	Alprazolam	105	17
Methylprednisolone	Methylprednisolone	103	83
Metformin Hcl	Metformin Hcl	102	27
Sertraline Hcl	Sertraline Hcl	96	28
Spironolactone	Spironolactone	95	32
Escitalopram Oxalate	Escitalopram Oxalate	93	28
Doxycycline Hyclate	Doxycycline Hyclate	89	70
Zolpidem Tartrate	Zolpidem Tartrate	86	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	83	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	80	26
Tizanidine Hcl	Tizanidine Hcl	80	41
Finasteride	Finasteride	78	25
Clonazepam	Clonazepam	74	11
Pregabalin	Pregabalin	69	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	69	23
Esomeprazole Magnesium	Esomeprazole Magnesium	68	23
Solifenacin Succinate	Solifenacin Succinate	68	22
Cefdinir	Cefdinir	65	56
Citalopram Hbr	Citalopram Hydrobromide	64	21
Estradiol	Estradiol	64	26
Naproxen	Naproxen	63	22
Ondansetron Odt	Ondansetron	63	28
Buspirone Hcl	Buspirone Hcl	61	24
Xarelto	Rivaroxaban	58	18
Venlafaxine Hcl Er	Venlafaxine Hcl	57	17
Diclofenac Sodium	Diclofenac Sodium	56	22
Glimepiride	Glimepiride	55	18
Lorazepam	Lorazepam	55	13
Triamcinolone Acetonide	Triamcinolone Acetonide	52	24
Enalapril Maleate	Enalapril Maleate	51	13
Irbesartan	Irbesartan	49	15
Doxazosin Mesylate	Doxazosin Mesylate	48	14
Atenolol	Atenolol	47	suppressed
Farxiga	Dapagliflozin Propanediol	47	14
Hydralazine Hcl	Hydralazine Hcl	47	16
Mirtazapine	Mirtazapine	47	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	suppressed
Myrbetriq	Mirabegron	46	suppressed
Ipratropium Bromide	Ipratropium Bromide	45	26
Dutasteride	Dutasteride	44	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	43	11
Valacyclovir	Valacyclovir Hcl	43	21
Fluoxetine Hcl	Fluoxetine Hcl	41	11
Memantine Hcl	Memantine Hcl	39	13
Synthroid	Levothyroxine Sodium	39	13
Ketoconazole	Ketoconazole	38	18
Trulicity	Dulaglutide	38	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	38	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	37	11
Baclofen	Baclofen	36	13
Fluconazole	Fluconazole	36	17
Meclizine Hcl	Meclizine Hcl	34	14
Risperidone	Risperidone	34	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	34	29
Flecainide Acetate	Flecainide Acetate	33	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	15
Ramipril	Ramipril	33	suppressed
Torsemide	Torsemide	31	suppressed
Cephalexin	Cephalexin	30	24
Topiramate	Topiramate	30	suppressed
Amiodarone Hcl	Amiodarone Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Bupropion Hcl Sr	Bupropion Hcl	29	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	29	11
Propranolol Hcl Er	Propranolol Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Donepezil Hcl	Donepezil Hcl	28	11
Nifedipine Er	Nifedipine	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Raloxifene Hcl	Raloxifene Hcl	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Bupropion Xl	Bupropion Hcl	26	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	21
Aripiprazole	Aripiprazole	25	suppressed
Azithromycin	Azithromycin	25	24
Colchicine	Colchicine	25	13
Dicyclomine Hcl	Dicyclomine Hcl	25	suppressed
Ibu	Ibuprofen	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	24	suppressed
Lansoprazole	Lansoprazole	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Levetiracetam	Levetiracetam	23	suppressed
Metolazone	Metolazone	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	18
Fenofibrate	Fenofibrate	20	suppressed
Nitroglycerin	Nitroglycerin	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	19	suppressed
Indapamide	Indapamide	19	suppressed
Linzess	Linaclotide	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	16
Nystatin	Nystatin	19	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	18	13
Testosterone	Testosterone	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Premarin	Estrogens, Conjugated	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	15	suppressed
Cefuroxime	Cefuroxime Axetil	14	14
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Glipizide	Glipizide	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Tiadylt Er	Diltiazem Hcl	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Saxagliptin Hcl	Saxagliptin Hcl	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	11	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Constulose	Lactulose	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Klor-Con 10	Potassium Chloride	11	suppressed
Lactulose	Lactulose	11	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$39.76 · 2 records	Novo Nordisk Inc	MOUNJARO, Ozempic, ZEPBOUND	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error